Inostics acquires from Johns Hopkins University an exclusive license for detection of PIK3CA
Subsidiary of Indivumed aims to develop DNA-based blood tests for individualizing cancer therapy
16-Nov-2009 -
Inostics GmbH announced it has obtained a world-wide exclusive license for detection of PIK3CA mutations from Johns Hopkins University (Baltimore, MD). The license grants Inostics, a subsidiary of Indivumed, the exclusive right to use digital PCR techniques and other technologies such as ...
mutations
PCR